RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF - CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD

Title:

RNAI AGENT INHIBITING PCSK9 GENE EXPRESSION AND APPLICATION THEREOF

Document Type and Number:

WIPO Patent Application WO/2023/134609

Kind Code:

A1

Abstract:

An RNAi agent inhibiting PCSK9 gene expression and an application thereof. The present invention relates to a modified double-stranded RNAi agent and an application thereof, and in particular to a double-stranded RNAi agent inhibiting PCSK9 gene expression and a pharmaceutical composition thereof, and an application of the double-stranded RNAi agent or the pharmaceutical composition thereof in the treatment of diseases mediated by PCSK9 expression.

More Like This:

JP2023552681	Improved formulation stabilization and lyophilization process improvements
WO/2020/197330	COMPOSITION FOR TREATING HEMOPHILIA BY MEANS OF BLOOD COAGULATION FACTOR VIII GENE INVERSION CORRECTION
WO/1994/013833	RIBOZYME AMPLIFIED DIAGNOSTICS

Inventors:

DONG YUNXIA (CN)
SHAO YU (CN)
SU XIAOYE (CN)
WANG LINGYU (CN)

Application Number:

PCT/CN2023/071189

Publication Date:

July 20, 2023

Filing Date:

January 09, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)

International Classes:

C12N15/113; A61K31/713; A61P3/06; A61P35/04

Foreign References:

CN104854242A	2015-08-19
CN101589143A	2009-11-25
CN112368381A	2021-02-12
CN113286888A	2021-08-20
CN109957565A	2019-07-02
CN109957567A	2019-07-02

Attorney, Agent or Firm:

CHINA PATENT AGENT (H.K.) LTD. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS

Next Patent: VIDEO DISPLAY AND INTERACTION METHOD AND APPARATUS, ELECTRONIC DEVICE, AND STORAGE MEDIUM